Sagimet Biosciences (SGMT) Other financing activities (2022 - 2025)
Sagimet Biosciences (SGMT) posted quarterly Other financing activities of -$300000.0 for Q4 2025, up 67.78% year-over-year from -$178809.2 in Q4 2024, and down 200.0% quarter-over-quarter from $300000.0 in Q3 2025.
Sagimet Biosciences (SGMT) Other financing activities (2022 - 2025) Analysis & Trends
Sagimet Biosciences' Other financing activities history runs 4 years deep, the most recent figure standing at -$300000.0 for Q4 2025.
- In Q4 2025, Other financing activities rose 67.78% year-over-year to -$300000.0; the TTM figure through Dec 2025 stood at $14000.0 (down 87.72% YoY), while the FY2024 annual figure was $114000.0, down 96.76% from the prior year.
- Other financing activities for Q4 2025 stood at -$300000.0, down from $300000.0 in the prior quarter.
- The five-year high for Other financing activities was $86.2 million in Q3 2023, with the low at -$82.6 million in Q4 2023.
- The 4-year median for Other financing activities is $77500.0 (2022), against an average of $368700.0.
- The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 150360.0% in 2023, then surged 98.87% in 2024.
- Sagimet Biosciences' Other financing activities stood at $55000.0 in 2022, then sank by 150360.0% to -$82.6 million in 2023, then soared by 98.87% to -$931000.0 in 2024, then jumped by 67.78% to -$300000.0 in 2025.
- Business Quant data shows SGMT's Other financing activities at -$300000.0 in Q4 2025, $300000.0 in Q3 2025, and -$931000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -300,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Dec 31, 2024 | -931,000.00 |
| Dec 31, 2024 | -931,000.00 |
| Sep 30, 2024 | 945,000.00 |
| Sep 30, 2024 | 945,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | -82.64 Mn |
| Dec 31, 2023 | -82.64 Mn |
| Sep 30, 2023 | 86.16 Mn |
| Sep 30, 2023 | 86.16 Mn |
| Jun 30, 2023 | -136,000.00 |
| Jun 30, 2023 | -136,000.00 |
| Mar 31, 2023 | 136,000.00 |
| Mar 31, 2023 | 136,000.00 |
| Dec 31, 2022 | 55,000.00 |
| Dec 31, 2022 | 55,000.00 |